B+L initiates Phase III program for glaucoma drug candidate licensed from Nicox
February 15th 2013Bausch + Lomb has started its Phase III clinical program of latanoprostene bunod licensed by Nicox S.A. to B+L. B+L’s drug candidate is meant to reduce IOP in patients with elevated IOP due to glaucoma or ocular hypertension.